

Thiago Quinaglia A C Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1963934/publications.pdf>

Version: 2024-02-01

46
papers

635
citations

758635

12
h-index

642321

23
g-index

48
all docs

48
docs citations

48
times ranked

1008
citing authors

#	ARTICLE	IF	CITATIONS
1	Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2022, 163, 108-118.	1.3	21
2	Change in Left Atrioventricular Coupling Index to Predict Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>Radiology</i> , 2022, 303, 317-326.	3.6	15
3	Rationale and design of the Brazilian diabetes study: a prospective cohort of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2022, 38, 523-529.	0.9	3
4	Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis. <i>Diagnostics</i> , 2022, 12, 814.	1.3	1
5	The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. <i>PLoS ONE</i> , 2022, 17, e0265767.	1.1	9
6	COVID-19 in Patients with Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 243-261.	0.8	3
7	Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 74.	2.7	44
8	Pre-clinical left ventricular myocardial remodeling in patients with Friedreich's ataxia: A cardiac MRI study. <i>PLoS ONE</i> , 2021, 16, e0246633.	1.1	6
9	Coronavirus disease-19: The multi-level, multi-faceted vasculopathy. <i>Atherosclerosis</i> , 2021, 322, 39-50.	0.4	32
10	Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus. <i>Nutrition and Diabetes</i> , 2021, 11, 17.	1.5	8
11	Quantitative Analysis of Adipose Depots by Using Chest CT and Associations with All-Cause Mortality in Chronic Obstructive Pulmonary Disease: Longitudinal Analysis from MESA Arthritis Ancillary Study. <i>Radiology</i> , 2021, 299, 703-711.	3.6	26
12	Pericardial disease in patients treated with immune checkpoint inhibitors. , 2021, 9, e002771.		33
13	Adipose tissue biomarkers and type 2 diabetes incidence in normoglycemic participants in the MESA Arthritis Ancillary Study: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003700.	3.9	2
14	Intrafamilial phenotypic heterogeneity related to a new DMD splice site variant. <i>Neuromuscular Disorders</i> , 2021, 31, 788-797.	0.3	1
15	Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial. <i>Diabetes and Metabolism</i> , 2021, 47, 101280.	1.4	6
16	Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: an active-controlled randomised trial. <i>Diabetes and Metabolism</i> , 2021, 48, 101304.	1.4	1
17	Association of Quantified Costal Cartilage Calcification and Long-Term Cumulative Blood Glucose Exposure: The Multi-Ethnic Study of Atherosclerosis. <i>Frontiers in Endocrinology</i> , 2021, 12, 785957.	1.5	1
18	Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232095924.	1.1	10

#	ARTICLE	IF	CITATIONS
19	Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 62.	1.2	9
20	State-of-the-Art Quantitative Assessment of Myocardial Ischemia by Stress Perfusion Cardiac Magnetic Resonance. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2019, 27, 491-505.	0.6	10
21	Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231986837.	1.1	2
22	Diabetic cardiomyopathy: factual or factoid?. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 61-69.	0.3	8
23	Central role of obesity in endothelial cell dysfunction and cardiovascular risk. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 87-97.	0.3	10
24	Assessment of Cardiotoxicity of Cancer Chemotherapy. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2019, 27, 533-544.	0.6	11
25	Differential impact of local and regional aortic stiffness on left ventricular remodeling. <i>Journal of Hypertension</i> , 2018, 36, 552-559.	0.3	14
26	Cardiac Involvement in Erdheim-Chester Disease. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e008531.	1.3	7
27	Cognitive and structural cerebral changes in amnesic mild cognitive impairment due to Alzheimer's disease after multicomponent training. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 473-480.	1.8	25
28	Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1045-1055.	2.3	109
29	Cardiac Sympathetic Activity and the Neuro-Humoral Theory on Heart Failure with Reduced Ejection Fraction: Have We Learned Enough?. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 191-192.	0.3	0
30	Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 808-809.	0.3	0
31	IMPACT OF STATIN THERAPY ON COLLAGEN TURNOVER AND LEFT VENTRICLE FUNCTION AFTER ST-ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL. <i>Journal of the American College of Cardiology</i> , 2017, 69, 156.	1.2	0
32	DOXORUBICIN-ASSOCIATED CARDIAC TISSUE REMODELING IN BREAST CANCER PATIENTS: A CARDIAC MAGNETIC RESONANCE STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1562.	1.2	0
33	Acute Sildenafil Use Reduces 24-Hour Blood Pressure Levels in Patients With Resistant Hypertension: A Placebo-Controlled, Crossover Trial. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1168-1172.	1.0	4
34	Biopsychosocial features and myocardial infarction in very elderly patients. <i>BBA Clinical</i> , 2015, 3, S3-S4.	4.1	0
35	Flow-mediated dilation: An evolving method. <i>Atherosclerosis</i> , 2015, 241, 143-144.	0.4	4
36	Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial. <i>Clinical Therapeutics</i> , 2014, 36, 961-966.	1.1	1

#	ARTICLE	IF	CITATIONS
37	Peri-Infarct Zone Characterized by Cardiac Magnetic Resonance Imaging is Directly Associated with the Inflammatory Activity During Acute Phase Myocardial Infarction. <i>Inflammation</i> , 2013, 37, 678-85.	1.7	12
38	Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2027-2036.	0.8	12
39	High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. <i>Journal of Human Hypertension</i> , 2013, 27, 225-230.	1.0	38
40	Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 698-702.	0.3	3
41	Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 698-702.	0.3	12
42	Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 698-702.	0.3	5
43	Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. <i>Journal of Human Hypertension</i> , 2011, 25, 532-538.	1.0	68
44	Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. <i>Journal of Human Hypertension</i> , 2011, 25, 656-664.	1.0	41
45	Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers. <i>Blood Pressure</i> , 2009, 18, 255-260.	0.7	0
46	Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers. <i>Blood Pressure</i> , 2009, 18, 255-260.	0.7	8